NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.

SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells. Oncotarget (2015) 0.83

LSD1 Histone Demethylase Assays and Inhibition. Methods Enzymol (2016) 0.76

Identification of downstream metastasis-associated target genes regulated by LSD1 in colon cancer cells. Oncotarget (2017) 0.75

Chromatin modifications and their function. Cell (2007) 55.98

CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44

Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30

Autophagy as a regulated pathway of cellular degradation. Science (2000) 17.27

Autophagy in cell death: an innocent convict? J Clin Invest (2005) 10.70

Autophagy in human health and disease. N Engl J Med (2013) 8.71

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57

LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53

Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13

Autophagy as a cell death and tumor suppressor mechanism. Oncogene (2004) 6.92

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2004) 4.20

The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ (2001) 4.07

Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65

Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res (2006) 2.62

Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis (2009) 2.54

Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer (2011) 2.42

Autophagy, mitochondrial quality control, and oncogenesis. Autophagy (2006) 2.17

LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat Cell Biol (2011) 1.76

Prostate cancer diagnosis and management. Lancet (1997) 1.68

Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer (2010) 1.63

Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc (2009) 1.56

Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry (2007) 1.44

The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem (2007) 1.42

p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther (2007) 1.40

The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res (2005) 1.34

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32

Epigenetic regulation of cancer growth by histone demethylases. Int J Cancer (2010) 1.23

Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res (2004) 1.18

Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther (2007) 1.12

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol (2008) 1.09

Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res (2012) 1.08

Cell death beyond apoptosis. Leukemia (2000) 1.06

The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther (2010) 0.93

Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression. Mol Ther Nucleic Acids (2012) 0.91

Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag (2006) 0.89

The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget (2014) 0.85

GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer. Carcinogenesis (2014) 0.84

KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget (2013) 0.84

Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Semin Oncol (1999) 0.82

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. Oncotarget (2014) 0.82

Organ specific Gst-pi expression of the metastatic androgen independent prostate cancer cells in nude mice. Prostate (2011) 0.81

Romidepsin: in the treatment of T-cell lymphoma. Drugs (2011) 0.77

A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review. Case Rep Oncol (2015) 0.75